MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2019 International Congress

    Effect of a Combined Treatment with Botulinum Toxin and Biofeedback Exercises in Pisa Syndrome

    A. Castagna, A. Crippa, D. Anastasi, M. Meloni, A. Montesano, A. Marzegan (Milano, Italy)

    Objective: To assess the efficacy of a combined botulinum neurotoxin (BoNT) treatment with biofeedback exercises in a single Parkinson Disease (PD) patient with Pisa Syndrome…
  • 2019 International Congress

    Tardive Cervical Dystonia: Treatment with Botulinum: Treatment with Botulinum Toxin Guided by Electromyography

    LFV. Vasconcellos, MS. Spitz, DN. Nassif, BRA. Andrade (Rio de Janeiro, Brazil)

    Objective: To describe the use of botulinum toxin in the treatment of tardive dystonia. Background: Tardive dystonia (TD) was recognized as a complication of dopamine…
  • 2019 International Congress

    Clinical Profile and Response to EMG-Guided Botulinum toxin (BTX) Injection in Writers’ Cramp (WC)- A Study of 25 Indian Patients

    P. Agarwal, P. Palekar (Mumbai, India)

    Objective: To study WC and its response to EMG-Guided BTX Background: Despite decades of use and popularity of BTX in WC, there is a paucity of…
  • 2019 International Congress

    Use of Chemodenervation for Secondary Limb Dystonia in Parkinson’s Disease: A Single Center Experience

    V. Veerappan, M. Brodsky (Portland, OR, USA)

    Objective: To describe characteristics of patients with secondary limb dystonia in Parkinson’s Disease, types of dystonia observed, and treatment/response with chemodenervation. Background: Dystonia can be…
  • 2019 International Congress

    Hemifacial Spasm and Related Comorbidities

    A. Akyol Gurses, N. Kiylioglu, A. Akyol (Aydin, Turkey)

    Objective: In this study, we evaluated the clinical findings, comorbidities and teratment responses in our HFS patients. Background: Hemifacial spasm (HFS) is a peripherally induced…
  • 2019 International Congress

    Central effects of botulinum neurotoxin injections in cervical dystonia – a longitudinal structural MRI-study

    D. Weise, C. Awissus, P. Baum, J. Classen, A. Villringer, P. Ragert, C. Weise (Leipzig, Germany)

    Objective: To investigate if cervical dystonia (CD) patients show structural grey matter changes and if these changes may be associated with previous botulinum neurotoxin (BoNT)…
  • 2019 International Congress

    Impact of fixed or flexible abobotulinumtoxinA injection intervals on patient outcomes: Analyses from a 3-year observational study following patients with cervical dystonia

    C. Colosimo, T. Chung, D. Charles, V. Misra, S. Om, P. Maisonobe (Terni, Italy)

    Objective: This post-hoc analysis assessed the impact of fixed or flexible injection schedules on outcomes in patients receiving abobotulinumtoxinA (aboBoNT-A) for cervical dystonia (CD) in…
  • 2019 International Congress

    Botulinum toxin injections reduce the symptoms of dystonic tremor and improve sensorimotor function for hand dexterity

    L. Rocchi, A. Latorre, G. Paparella, E. Menozzi, L. Peppoloni, F. Valero-Cuevas, C. Cordivari, K. Bhatia, J. Rothwell (London, United Kingdom)

    Objective: To assess improvement in hand function following therapy with botulinum toxin in patients with dystonic tremor (DT). Background: Treatment of dystonic tremor (DT) with…
  • 2019 International Congress

    Botulinum toxin for the management of dystonic scoliosis in children

    D. Ferman, T. Sanger (Los Angeles, CA, USA)

    Objective: To report the use of botulinum toxin (BoNT) for the treatment of dystonic scoliosis in children with cerebral palsy. Background: Children with CP and…
  • 2019 International Congress

    Moving ear syndrome secondary to bromopride and response to botulinum toxin

    F. Sekeff-Sallem, J. Pedroso, O. Barsottini (Sao Paulo, Brazil)

    Objective: Report a case of a rare drug-induced movement disorder, the moving ear syndrome, describe its phenomenology and its treatment with botulinum toxin Background: Since…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 21
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley